Different inflammatory responses induced by three LDL-lowering apheresis columns.
Low-density lipoprotein (LDL) apheresis is well-established in selected patients with uncontrolled LDL levels. As such treatment affects biomarkers important in atherosclerosis and acute coronary syndromes, we systematically compared the inflammatory response induced by three LDL apheresis columns. Three patients with heterozygous familial hypercholesterolemia participated in a cross-over study with six consecutive treatments with three different LDL apheresis columns: DL-75 (whole blood adsorption), LA-15 (plasma adsorption), and EC-50W (plasma filtration). Biochemical parameters and inflammatory biomarkers, including complement activation products and 27 cytokines, chemokines, and growth factors were measured before and after treatment. Complement was activated through the alternative pathway. The final end product sC5b-9 increased significantly (P < 0.01) and equally with all devices, whereas the anaphylatoxins C3a and C5a were lower by use of the adsorption columns. Hs-CRP was reduced by 77% (DL-75), 72% (LA-15), and 43% (EC-50W). The cytokines were consistently either increased (IL-1ra, IP-10, MCP-1), decreased (IFN-gamma, TNF-alpha, RANTES, PDGF, VEGF), or hardly changed (including IL-6, IL8, MIP-1alphabeta) during treatment. The changes were in general less pronounced with the adsorption columns. All columns reduced LDL significantly and to the same extent. In conclusion, three LDL-apheresis devices with equal cholesterol-lowering effect differed significantly with respect to the inflammatory response.
Hovland
Anders
A
Coronary Care Unit, Department of Internal Medicine, Nordland Hospital, Bodø, Norway. anders.w.hovland@gmail.com
Hardersen
Randolf
R
Sexton
Joe
J
Mollnes
Tom Eirik
TE
Lappegård
Knut Tore
KT
D000328:Adult; D001781:Blood Component Removal / Q000009:adverse effects*; D002097:C-Reactive Protein / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood*; D015938:Complement Membrane Attack Complex / Q000032:analysis; D018592:Cross-Over Studies; D016207:Cytokines / Q000097:blood; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000628:therapy*; D007249:Inflammation / Q000209:etiology*; D008297:Male; D008875:Middle Aged
D008078:Cholesterol, LDL; D015938:Complement Membrane Attack Complex; D016207:Cytokines; D002097:C-Reactive Protein